Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Primary CNS Lymphoma

Interventions

DRUG

Hyperpolarized pyruvate (13C)

Given intravenously (IV) injection prior to imaging

PROCEDURE

Magnetic resonance imaging (MRI)

MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete

Trial Locations (1)

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

James Rubenstein

OTHER

NCT04656431 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter